Skip to content
HPB-ALL
Tissue
Peripheral blood
Disease
Precursor T-cell acute lymphoblastic leukemia
Metastatic site
Peripheral blood (systemic T-ALL)
Synonyms
HPB/ALL, HPBALL, FCCH1018

Documents

HPB-ALL

Cell line · Product number 302895

HPB-ALL is a human precursor T-cell acute lymphoblastic leukemia (T-ALL) cell line established from the peripheral blood of a 14-year-old Japanese male pa...

€430.00excl. tax and shipping

Customization / Recommendations

In stock
Lot
Recommended (freshest lot)
  • CoA
1

01General information

Description

HPB-ALL is a human precursor T-cell acute lymphoblastic leukemia (T-ALL) cell line established from the peripheral blood of a 14-year-old Japanese male patient. The line grows in suspension with lymphocyte-like morphology. HPB-ALL harbors a complex TP53 mutational profile with eight mutations across heterozygous and homozygous states, reflecting the genetic complexity of T-ALL at diagnosis. The line expresses T cell surface markers consistent with T-ALL biology, making it relevant for studies of T lymphoblast leukemia pathogenesis and drug responses.

HPB-ALL is applicable in studies of T-ALL biology, TP53 multi-mutant phenotype, anti-leukemic drug sensitivity (glucocorticoids, vincristine, asparaginase, nelarabine), Notch and JAK-STAT pathway analysis, and comparative studies within the T-ALL cell line panel. It is suitable for in vitro pharmacological assays and xenograft models in immunocompromised hosts for preclinical T-ALL drug evaluation. Doubling time approximately 50 hours.

Tissue
Peripheral blood
Disease
Precursor T-cell acute lymphoblastic leukemia
Metastatic site
Peripheral blood (systemic T-ALL)
Applications
T-ALL biology; TP53 multi-mutant phenotype; anti-leukemic drug sensitivity (glucocorticoids, vincristine, asparaginase, nelarabine); Notch/JAK-STAT pathways; xenograft models; T-ALL panel comparative studies
Synonyms
  • HPB/ALL
  • HPBALL
  • FCCH1018

02Classification

Organism
Human
Sex
Male
Growth properties
Suspension
Biosafety level
1

03Characteristics

Morphology
Lymphoblast-like
Cell type
T-cell
Doubling time
~50 hours

04Identifiers

Citation
HPB-ALL (Cytion catalog number 302895)
NCBI TaxID
9606
Cellosaurus
CVCL_1820

05Expression and susceptibility

Mutational profile
Mutation: p.Arg465His, Unspecified; Mutation: p.Ala134Ser, Unspecified; Mutation: p.Leu1574Pro, Heterozygous; Mutation: p.Asp2442fs*39, Heterozygous; Mutation: p.Arg159Ser, Unspecified; Mutation: p.Cys124Ter, Homozygous; Mutation: p.Arg273Cys, Unspecified; Mutation: p.Ser121Ter, Unspecified

06Handling and culture

Culture medium
RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
Supplements
Supplement the medium with 10% FBS
Dissociation reagent
dilution
Subculturing
Dilute the culture to 2–5 × 10⁵ cells/ml with fresh pre-warmed complete medium twice per week. No enzymatic dissociation required.
Split ratio
1 : 10 split
Seeding density
3-5*10^5/ml
Fluid renewal
Subculture : 2 times/week
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 200 x g for 5 minutes, carefully discard the supernatant containing freezing medium.

  7. Follow the procedure described under Post-Thaw Recovery

07Quality control and cryopreservation

Freeze medium
As a cryopreservation medium, we use complete growth medium + 10% DMSO for adequate post-thaw viability.
Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

08Donor

Donor age
14 years
Ethnicity
Japanese

10Product details

Composition table